Iris recognition makes no difference to wavefront-guided LASIK outcomes

Article

There are no statistically significant differences in outcomes when wavefront-guided LASIK is performed with or without iris recognition (IR), according to a report published in the September 2008 issue of the Journal of Cataract and Refractive Surgery.

There are no statistically significant differences in outcomes when wavefront-guided LASIK is performed with or without iris recognition (IR), according to a report published in the September 2008 issue of the Journal of Cataract and Refractive Surgery.

Theeraptep Tantayakom and colleagues from the Shiley Eye Center, University of California San Diego, California, US conducted a retrospective analysis of 112 eyes of 64 patients who had undergone wavefront-guided LASIK using the VISX CustomVue S4 IR platform (AMO) for either myopia or myopic astigmatism. The safety, efficacy, predictability and need for enhancement at three-month follow-up were analyzed and compared between those in the IR group and those in the non-IR group.

At three-months follow-up, 93% of eyes in the non-IR group and all eyes in the IR group had the same best spectacle-corrected visual acuity (BSCVA) as preoperatively or had gained one or two lines. No eye in either group lost more than one line (p=0.12). Furthermore, 96% of eyes in the IR group and 93% of eyes in the non-IR group were within ±0.50 D of the postoperative manifest refraction spherical equivalent (p=0.24) and all eyes were within ±1 D of emmetropia. Just four eyes in the IR group and 11 in the non-IR group required enhancements during the follow-up period (p=0.1).

It was the conclusion of Dr Tantayakom and co-workers that there are no differences in measured outcomes of wavefront-guided LASIK, whether IR is used or not.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.